A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE EFFECTS OF DOCOSAHEXAE

DOCOSAHEXAE 作用的随机双盲安慰剂对照试验

• 批准号: 8166913
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166913
• 关键词: Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animals; Antioxidants; Blood; Brain; Cerebrospinal Fluid; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Diet Habits; Dietary intake; Docosahexaenoic Acids; Epidemiologic Studies; Funding; Grant; Gray unit of radiation dose; Hippocampus (Brain); Human; Individual; Institution; Memory; Micronutrients; Mus; Omega-3 Fatty Acids; Phospholipids; Placebos; Plasma; Randomized; Rattus; Research; Research Personnel; Resources; Sampling; Source; Supplementation; Testing; Thinking; United States National Institutes of Health; Urine; double-blind placebo controlled trial; functional decline; human subject

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Epidemiological studies show that Docosahexaenoic Acid (DHA) supplementation slows the progression of cognitive and functional decline over 18 months in mild to moderate Alzheimer s Disease (AD). DHA, an omega-3 fatty acid has been shown to reduce brain levels of beta-amyloid (A¿) in mice and rat models of AD, as well as have antioxidant effects on the cerebrospinal fluid. Individuals with AD have significantly decreased brain levels of DHA in frontal grey and hippocampus phospholipids compared to controls (as seen in previous human studies), as well as significantly lower plasma levels of DHA compared to control subjects. Since dietary intake of DHA can increase plasma levels of DHA in human subjects, and since dietary intake and plasma levels correlate with brain levels in animals, treatment of AD with DHA supplementation is plausible, and thus proposed in this study. This study will evaluate the effects of DHA versus placebo in subjects with mild to moderate AD over an 18 month period by administering memory and thinking tests. Blood and urine samples will also be collected in this study to examine the micronutrients related to dietary habits which may reveal DHA effects.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 对于中心来说，它不一定是研究者的机构。 流行病学研究表明，补充二十二碳六烯酸 (DHA) 可以在 18 个月内减缓轻度至中度阿尔茨海默氏病 (AD) 的认知和功能下降的进展，DHA 是一种 omega-3 脂肪酸，已被证明可以降低大脑中 β-淀粉样蛋白的水平。 (A¿) 在 AD 小鼠和大鼠模型中具有抗氧化作用，并且对脑脊液具有抗氧化作用。 AD 患者大脑额叶灰质中的 DHA 水平显着降低。与对照组相比，DHA 和海马磷脂水平显着降低（如之前的人类研究所示），并且与对照组相比，DHA 血浆水平显着降低，因为膳食摄入 DHA 可以增加人类受试者的血浆 DHA 水平，并且由于膳食摄入和血浆 DHA 水平显着降低。 DHA 水平与动物大脑水平相关，因此通过补充 DHA 治疗 AD 是合理的，因此本研究提出了这一建议。 这项研究将通过记忆和思维测试来评估 DHA 与安慰剂在 18 个月内对轻度至中度 AD 受试者的影响。这项研究还将收集血液和尿液样本，以检查可能与饮食习惯相关的微量营养素。揭示 DHA 效果。